Hoth Therapeutics, Inc. (HOTH)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Hoth Therapeutics, Inc. (HOTH)
Company Performance

Current Price

as of Oct 16, 2024

$0.93

P/E Ratio

N/A

Market Cap

$6.42M

Description

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerHOTH
  • Price$0.9303+4.94%

Trading Information

  • Market Cap$6.42M
  • Float99.07%
  • Average Daily Volume (1m)772,993
  • Average Daily Volume (3m)3,931,721
  • EPS-$1.69

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$1.63M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$1.65M
  • EV-$3.36M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.53
Documents
SEC Filings
8-K (2024-08-07)
8-K (2024-06-17)
8-K (2024-03-28)
8-K (2024-01-09)
8-K (2023-10-05)
8-K (2023-09-15)
8-K (2023-08-21)
8-K (2023-08-17)
8-K (2023-06-06)
8-K (2023-02-28)
10-Q (2024-08-09)
10-Q (2024-05-14)
10-Q (2023-11-13)
10-Q (2023-08-11)
10-Q (2023-05-15)
10-K (2024-03-28)
10-K (2023-03-31)
Factset
Factset Business Description
Factset Street Account
Hoth Therapeutics reports Q3 GAAP EPS ($0.60) vs year-ago ($2.05) - 10-Q ($1.13, 0.00) (2023-11-13T21:36:23Z)
Hoth Therapeutics granted FDA pre-IND meeting for HT-KIT, treatment for cancer patients ($1.52, 0.00) (2023-10-02T12:35:52Z)
Hoth Therapeutics discloses formation of new subsidiary focused on drug discovery for rare diseases utilizing artificial intelligence - 8-K ($1.38, 0.00) (2023-10-05T12:18:56Z)
Hoth Therapeutics announces successful completion of Pre-IND meeting with FDA regarding development of Hoth's HT-KIT ($1.13, 0.00) (2023-11-14T13:39:32Z)